Useful Cases of Patients With Developmental Disorders Improved by Oral Administration of LPS Derived from Pantoea

Atsutomo Morishima1, Ran Zhang2,3, Takema Nagaoka2

  • 1Lavita Integrative Medical Clinic, Osaka, Japan atsu5426@yahoo.co.jp.

Anticancer Research
|July 31, 2020
PubMed
Abstract

Insights

Oral administration of Pantoea agglomerans lipopolysaccharide (LPSp) improved symptoms in children with developmental disorders. This suggests LPSp may be a novel therapeutic option for conditions like autism spectrum disorder and ADHD.

Area of Science:

  • Neuroscience
  • Immunology
  • Microbiology

Background:

  • Microglial dysfunction is linked to developmental disorders.
  • Pantoea agglomerans lipopolysaccharide (LPSp) normalizes microglial phagocytosis and reduces inflammation in mice.
  • This study investigates LPSp's efficacy in human patients.

Purpose of the Study:

  • To evaluate the therapeutic potential of LPSp in pediatric patients with developmental disorders.
  • To assess the impact of LPSp on symptoms associated with autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD).

Main Methods:

  • A trial involving five pediatric patients diagnosed with ASD/ADHD.
  • Patients received 0.75 or 1 mg/day of LPSp for at least six months, alongside standard therapies.
  • Parental survey questionnaires were used for evaluation via the Numerical Rating Scale.

Main Results:

  • All patients showed significant improvements in behavior, verbal ability, and communication.
  • The study observed positive outcomes in core symptoms of ASD/ADHD.

Conclusions:

  • Oral LPSp administration shows promise as a new treatment for developmental disorders.
  • LPSp may offer a novel therapeutic avenue where current treatments are limited.